Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Bio-Rad Laboratories, Inc.'s (BIO) robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics areas. The company's emphasis on international expansion is encouraging. Meanwhile, the persistent softness in the Biopharma segment and negative economic impacts on Bio-Rad's margin performance raise concerns. In the past ye ...